[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
[引用][C] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - cir.nii.ac.jp
The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer
patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and …
patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and …
[PDF][PDF] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang… - Journal of Thoracic …, 2017 - cdn.amegroups.cn
Background: The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang… - Journal of thoracic …, 2017 - pubmed.ncbi.nlm.nih.gov
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang, G Chen… - Journal of Thoracic …, 2017 - europepmc.org
Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
[HTML][HTML] The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang… - Journal of Thoracic …, 2017 - jtd.amegroups.org
Background: The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a …
Y Zhang, S Miao, F Wang, W Fang… - Journal of Thoracic …, 2017 - jtd.amegroups.org
Background: The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …